Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

Active:	No
Cancer Type:	Gynecologic Cancers Primary Peritoneal Cancer Unknown Primary	NCT ID:	NCT05257408
Trial Phases:	Phase III	Protocol IDs:	CORT125134-556 (primary) NCI-2022-07960 GOG-3073
Eligibility:	18 Years and older, Female	Study Type:	Treatment
Study Sponsor:	Corcept Therapeutics Inc
NCI Full Details:	http://clinicaltrials.gov/show/NCT05257408

Summary

The primary objective of this study is to evaluate progression-free survival (PFS) by
blinded independent central review (BICR) in patients treated with intermittent regimen
of relacorilant in combination with nab-paclitaxel compared with patients treated with
nab-paclitaxel monotherapy.

Objectives

As there are no currently approved therapies or effective standard of care for heavily
pretreated patients with ovarian cancer who have exhausted single-agent chemotherapy
and/or bevacizumab, the combination of intermittently administered relacorilant and
nab-paclitaxel may demonstrate a substantial improvement without increased toxicity
compared with nab-paclitaxel.

Patients will receive study treatment until confirmed progressive disease (PD) or
unacceptable toxicity. All patients will be followed for the collection of study
endpoints, inclusive of disease progression and survival.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.